Review



s blebbistatin  (Toronto Research Chemicals)


Bioz Verified Symbol Toronto Research Chemicals is a verified supplier
Bioz Manufacturer Symbol Toronto Research Chemicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Toronto Research Chemicals s blebbistatin
    S Blebbistatin, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+blebbistatin/(S)-(-)-Blebbistatin/pm41916979-299-23-24
    Average 93 stars, based on 17 article reviews
    s blebbistatin - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Quantitation Assay:

    Article Title: Myosin-II Negatively Regulates Minor Process Extension and the Temporal Development of Neuronal Polarity
    Article Snippet: Drug Treatment Forebrain cultures were maintained in M199 medium or M199 medium supplemented with 50 μM (S)-(−)-Blebbistatin (Toronto Research Chemicals, Inc., North York, ON, Canada), 500 nM ML-7 (Biomol Research Laboratories Inc., Plymouth Meeting PA), 10 μM Y-27632 (CN Biosciences supplied by Calbiochem-Novabiochem Corp, San Diego, CA), a combination of ML-7 and Y-27632, or DMSO vehicle.

    Article Title: Myosin-II Negatively Regulates Minor Process Extension and the Temporal Development of Neuronal Polarity
    Article Snippet: Forebrain cultures were maintained in M199 medium or M199 medium supplemented with 50 μM (S)-(−)-Blebbistatin (Toronto Research Chemicals, Inc., North York, ON, Canada), 500 nM ML-7 (Biomol Research Laboratories Inc., Plymouth Meeting PA), 10 μM Y-27632 (CN Biosciences supplied by Calbiochem-Novabiochem Corp, San Diego, CA), a combination of ML-7 and Y-27632, or DMSO vehicle.

    Article Title: Interaction with surrounding normal epithelial cells influences signalling pathways and behaviour of Src-transformed cells
    Article Snippet: Where indicated, the following inhibitors were used: 4-AP (2 mM, Sigma-Aldrich), (S)-(—)-Blebbistatin (30 μM, Toronto Research Chemicals, ON, Canada), U0126 (10 μM, Promega), PF573228 (20 μM, TOCRIS Bioscience, Ellisville, MO), and αGA (50 μM, Sigma-Aldrich).

    Article Title: MDCK cells expressing constitutively active Yes-associated protein (YAP) undergo apical extrusion depending on neighboring cell status
    Article Snippet: The chemical inhibitors cytochalasin D (0.4 μM), JTE-013 (10 μM) and PF-4708671 (10 μM) were purchased from Sigma-Aldrich; bisindolylmaleimide I (10 μM), LY294002 (10 μM) and rapamycin (0.1 μM) from Calbiochem; withaferin A (2.5 μM) from Santa Cruz; U0126 (10 μM) from Promega; and (S)-(-)-blebbistatin (30 μM) from Toronto Research Chemicals.

    Article Title: Elimination of LMP1-expressing cells from a monolayer of gastric cancer AGS cells
    Article Snippet: For inhibition of exosome secretion, cells were treated with 10 μM GW4869 (Cayman) for 24–48 h before harvesting. (S)-(−)-blebbistatin (30 μM; Toronto Research Chemicals), Y27632 (10 μM; Cayman) and ML-7 (10 μM; Cayman) were used to inhibit the Rho/myosin-II pathway.

    Labeling:

    Article Title: Myosin-II Negatively Regulates Minor Process Extension and the Temporal Development of Neuronal Polarity
    Article Snippet: Drug Treatment Forebrain cultures were maintained in M199 medium or M199 medium supplemented with 50 μM (S)-(−)-Blebbistatin (Toronto Research Chemicals, Inc., North York, ON, Canada), 500 nM ML-7 (Biomol Research Laboratories Inc., Plymouth Meeting PA), 10 μM Y-27632 (CN Biosciences supplied by Calbiochem-Novabiochem Corp, San Diego, CA), a combination of ML-7 and Y-27632, or DMSO vehicle.

    Article Title: Myosin-II Negatively Regulates Minor Process Extension and the Temporal Development of Neuronal Polarity
    Article Snippet: Forebrain cultures were maintained in M199 medium or M199 medium supplemented with 50 μM (S)-(−)-Blebbistatin (Toronto Research Chemicals, Inc., North York, ON, Canada), 500 nM ML-7 (Biomol Research Laboratories Inc., Plymouth Meeting PA), 10 μM Y-27632 (CN Biosciences supplied by Calbiochem-Novabiochem Corp, San Diego, CA), a combination of ML-7 and Y-27632, or DMSO vehicle.

    Article Title: Interaction with surrounding normal epithelial cells influences signalling pathways and behaviour of Src-transformed cells
    Article Snippet: Where indicated, the following inhibitors were used: 4-AP (2 mM, Sigma-Aldrich), (S)-(—)-Blebbistatin (30 μM, Toronto Research Chemicals, ON, Canada), U0126 (10 μM, Promega), PF573228 (20 μM, TOCRIS Bioscience, Ellisville, MO), and αGA (50 μM, Sigma-Aldrich).

    Article Title: MDCK cells expressing constitutively active Yes-associated protein (YAP) undergo apical extrusion depending on neighboring cell status
    Article Snippet: The chemical inhibitors cytochalasin D (0.4 μM), JTE-013 (10 μM) and PF-4708671 (10 μM) were purchased from Sigma-Aldrich; bisindolylmaleimide I (10 μM), LY294002 (10 μM) and rapamycin (0.1 μM) from Calbiochem; withaferin A (2.5 μM) from Santa Cruz; U0126 (10 μM) from Promega; and (S)-(-)-blebbistatin (30 μM) from Toronto Research Chemicals.

    Article Title: Elimination of LMP1-expressing cells from a monolayer of gastric cancer AGS cells
    Article Snippet: For inhibition of exosome secretion, cells were treated with 10 μM GW4869 (Cayman) for 24–48 h before harvesting. (S)-(−)-blebbistatin (30 μM; Toronto Research Chemicals), Y27632 (10 μM; Cayman) and ML-7 (10 μM; Cayman) were used to inhibit the Rho/myosin-II pathway.

    Incubation:

    Article Title: Myosin-II Negatively Regulates Minor Process Extension and the Temporal Development of Neuronal Polarity
    Article Snippet: Drug Treatment Forebrain cultures were maintained in M199 medium or M199 medium supplemented with 50 μM (S)-(−)-Blebbistatin (Toronto Research Chemicals, Inc., North York, ON, Canada), 500 nM ML-7 (Biomol Research Laboratories Inc., Plymouth Meeting PA), 10 μM Y-27632 (CN Biosciences supplied by Calbiochem-Novabiochem Corp, San Diego, CA), a combination of ML-7 and Y-27632, or DMSO vehicle.

    Article Title: Myosin-II Negatively Regulates Minor Process Extension and the Temporal Development of Neuronal Polarity
    Article Snippet: Forebrain cultures were maintained in M199 medium or M199 medium supplemented with 50 μM (S)-(−)-Blebbistatin (Toronto Research Chemicals, Inc., North York, ON, Canada), 500 nM ML-7 (Biomol Research Laboratories Inc., Plymouth Meeting PA), 10 μM Y-27632 (CN Biosciences supplied by Calbiochem-Novabiochem Corp, San Diego, CA), a combination of ML-7 and Y-27632, or DMSO vehicle.

    Article Title: Interaction with surrounding normal epithelial cells influences signalling pathways and behaviour of Src-transformed cells
    Article Snippet: Where indicated, the following inhibitors were used: 4-AP (2 mM, Sigma-Aldrich), (S)-(—)-Blebbistatin (30 μM, Toronto Research Chemicals, ON, Canada), U0126 (10 μM, Promega), PF573228 (20 μM, TOCRIS Bioscience, Ellisville, MO), and αGA (50 μM, Sigma-Aldrich).

    Article Title: MDCK cells expressing constitutively active Yes-associated protein (YAP) undergo apical extrusion depending on neighboring cell status
    Article Snippet: The chemical inhibitors cytochalasin D (0.4 μM), JTE-013 (10 μM) and PF-4708671 (10 μM) were purchased from Sigma-Aldrich; bisindolylmaleimide I (10 μM), LY294002 (10 μM) and rapamycin (0.1 μM) from Calbiochem; withaferin A (2.5 μM) from Santa Cruz; U0126 (10 μM) from Promega; and (S)-(-)-blebbistatin (30 μM) from Toronto Research Chemicals.

    Article Title: Elimination of LMP1-expressing cells from a monolayer of gastric cancer AGS cells
    Article Snippet: For inhibition of exosome secretion, cells were treated with 10 μM GW4869 (Cayman) for 24–48 h before harvesting. (S)-(−)-blebbistatin (30 μM; Toronto Research Chemicals), Y27632 (10 μM; Cayman) and ML-7 (10 μM; Cayman) were used to inhibit the Rho/myosin-II pathway.



    Similar Products

    93
    Toronto Research Chemicals s blebbistatin
    S Blebbistatin, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+blebbistatin/(S)-(-)-Blebbistatin/pm41916979-299-23-24
    Average 93 stars, based on 1 article reviews
    s blebbistatin - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    95
    MedChemExpress nitro blebbistatin cayman chemical
    Nitro Blebbistatin Cayman Chemical, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+blebbistatin/Blebbistatin/pm41201825-288-25-34
    Average 95 stars, based on 1 article reviews
    nitro blebbistatin cayman chemical - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    93
    Tocris blebbistatin
    Figure 4. Geometrically tuned environments lead to functional crypt-villi-like formation. A) Schematic of the process to seed Caco-2 cells onto specif- ically bioprinted constructs to force morphogenesis. B) Geometries used with areas and edge effect values provided. C) MUC2 qRT-PCR trials (n = 3) comparing size based on the specific shape reported with mean and standard deviation. Significance is provided above the plots and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. D) MUC2 expression compiled (n = 3) and compared to the various edge effect values. The line of best fit was produced using GraphPad PRISM analysis software. E) Brightfield images of abstract shape bioprinted arrays at day 0 and day 5 of incubation. F) MUC2 expression of abstract shape trials (n = 3) compared to a control sample and 0.07 mm2 triangle array. Significance is provided above the plot and is calculated using one-way ANOVA. G) Brightfield images of <t>blebbistatin</t> dosage trial of abstract shape array at day 5. H) MUC2 expression (n = 3) of 0.07 mm2 triangle array and abstract shape array under blebbistatin dosing compared to a control sample incubated with basal media only reported with mean and standard deviation. Shaded regions represent blebbistatin exposure. Significance is provided above the plot and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Blebbistatin, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+blebbistatin/(S)-(-)-Blebbistatin/pm40545928-363-8-9
    Average 93 stars, based on 1 article reviews
    blebbistatin - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    Toronto Research Chemicals group 2 uses s
    Figure 4. Geometrically tuned environments lead to functional crypt-villi-like formation. A) Schematic of the process to seed Caco-2 cells onto specif- ically bioprinted constructs to force morphogenesis. B) Geometries used with areas and edge effect values provided. C) MUC2 qRT-PCR trials (n = 3) comparing size based on the specific shape reported with mean and standard deviation. Significance is provided above the plots and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. D) MUC2 expression compiled (n = 3) and compared to the various edge effect values. The line of best fit was produced using GraphPad PRISM analysis software. E) Brightfield images of abstract shape bioprinted arrays at day 0 and day 5 of incubation. F) MUC2 expression of abstract shape trials (n = 3) compared to a control sample and 0.07 mm2 triangle array. Significance is provided above the plot and is calculated using one-way ANOVA. G) Brightfield images of <t>blebbistatin</t> dosage trial of abstract shape array at day 5. H) MUC2 expression (n = 3) of 0.07 mm2 triangle array and abstract shape array under blebbistatin dosing compared to a control sample incubated with basal media only reported with mean and standard deviation. Shaded regions represent blebbistatin exposure. Significance is provided above the plot and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Group 2 Uses S, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+blebbistatin/(S)-(-)-Blebbistatin/10__1038_slash_s44385___025___00026___w-282-0-5
    Average 93 stars, based on 1 article reviews
    group 2 uses s - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    90
    Fisher Scientific blebbistatin s-nitro blebbistatin
    Figure 4. Geometrically tuned environments lead to functional crypt-villi-like formation. A) Schematic of the process to seed Caco-2 cells onto specif- ically bioprinted constructs to force morphogenesis. B) Geometries used with areas and edge effect values provided. C) MUC2 qRT-PCR trials (n = 3) comparing size based on the specific shape reported with mean and standard deviation. Significance is provided above the plots and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. D) MUC2 expression compiled (n = 3) and compared to the various edge effect values. The line of best fit was produced using GraphPad PRISM analysis software. E) Brightfield images of abstract shape bioprinted arrays at day 0 and day 5 of incubation. F) MUC2 expression of abstract shape trials (n = 3) compared to a control sample and 0.07 mm2 triangle array. Significance is provided above the plot and is calculated using one-way ANOVA. G) Brightfield images of <t>blebbistatin</t> dosage trial of abstract shape array at day 5. H) MUC2 expression (n = 3) of 0.07 mm2 triangle array and abstract shape array under blebbistatin dosing compared to a control sample incubated with basal media only reported with mean and standard deviation. Shaded regions represent blebbistatin exposure. Significance is provided above the plot and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Blebbistatin S Nitro Blebbistatin, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+blebbistatin/blebbistatin+s+nitro+blebbistatin/pm40492621-270-16-19
    Average 90 stars, based on 1 article reviews
    blebbistatin s-nitro blebbistatin - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    96
    Tocris blebbistatin tocris
    Figure 4. Geometrically tuned environments lead to functional crypt-villi-like formation. A) Schematic of the process to seed Caco-2 cells onto specif- ically bioprinted constructs to force morphogenesis. B) Geometries used with areas and edge effect values provided. C) MUC2 qRT-PCR trials (n = 3) comparing size based on the specific shape reported with mean and standard deviation. Significance is provided above the plots and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. D) MUC2 expression compiled (n = 3) and compared to the various edge effect values. The line of best fit was produced using GraphPad PRISM analysis software. E) Brightfield images of abstract shape bioprinted arrays at day 0 and day 5 of incubation. F) MUC2 expression of abstract shape trials (n = 3) compared to a control sample and 0.07 mm2 triangle array. Significance is provided above the plot and is calculated using one-way ANOVA. G) Brightfield images of <t>blebbistatin</t> dosage trial of abstract shape array at day 5. H) MUC2 expression (n = 3) of 0.07 mm2 triangle array and abstract shape array under blebbistatin dosing compared to a control sample incubated with basal media only reported with mean and standard deviation. Shaded regions represent blebbistatin exposure. Significance is provided above the plot and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
    Blebbistatin Tocris, supplied by Tocris, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/s+blebbistatin/(%2B%2F-)-Blebbistatin/pmc12168025__pnas%2E2417676122%2Esapp-71-15-16
    Average 96 stars, based on 1 article reviews
    blebbistatin tocris - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    Figure 4. Geometrically tuned environments lead to functional crypt-villi-like formation. A) Schematic of the process to seed Caco-2 cells onto specif- ically bioprinted constructs to force morphogenesis. B) Geometries used with areas and edge effect values provided. C) MUC2 qRT-PCR trials (n = 3) comparing size based on the specific shape reported with mean and standard deviation. Significance is provided above the plots and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. D) MUC2 expression compiled (n = 3) and compared to the various edge effect values. The line of best fit was produced using GraphPad PRISM analysis software. E) Brightfield images of abstract shape bioprinted arrays at day 0 and day 5 of incubation. F) MUC2 expression of abstract shape trials (n = 3) compared to a control sample and 0.07 mm2 triangle array. Significance is provided above the plot and is calculated using one-way ANOVA. G) Brightfield images of blebbistatin dosage trial of abstract shape array at day 5. H) MUC2 expression (n = 3) of 0.07 mm2 triangle array and abstract shape array under blebbistatin dosing compared to a control sample incubated with basal media only reported with mean and standard deviation. Shaded regions represent blebbistatin exposure. Significance is provided above the plot and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

    Journal: Advanced healthcare materials

    Article Title: Geometrically Controlled WNT Activation Drives Intestinal Morphogenesis.

    doi: 10.1002/adhm.202502832

    Figure Lengend Snippet: Figure 4. Geometrically tuned environments lead to functional crypt-villi-like formation. A) Schematic of the process to seed Caco-2 cells onto specif- ically bioprinted constructs to force morphogenesis. B) Geometries used with areas and edge effect values provided. C) MUC2 qRT-PCR trials (n = 3) comparing size based on the specific shape reported with mean and standard deviation. Significance is provided above the plots and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. D) MUC2 expression compiled (n = 3) and compared to the various edge effect values. The line of best fit was produced using GraphPad PRISM analysis software. E) Brightfield images of abstract shape bioprinted arrays at day 0 and day 5 of incubation. F) MUC2 expression of abstract shape trials (n = 3) compared to a control sample and 0.07 mm2 triangle array. Significance is provided above the plot and is calculated using one-way ANOVA. G) Brightfield images of blebbistatin dosage trial of abstract shape array at day 5. H) MUC2 expression (n = 3) of 0.07 mm2 triangle array and abstract shape array under blebbistatin dosing compared to a control sample incubated with basal media only reported with mean and standard deviation. Shaded regions represent blebbistatin exposure. Significance is provided above the plot and is calculated using one-way ANOVA with Tukey’s Multiple Comparison test. Significance levels are represented as p values with symbols corresponding to *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

    Article Snippet: The culture medium was supplemented with 50 μM blebbistatin (Tocris 1852).

    Techniques: Functional Assay, Construct, Quantitative RT-PCR, Standard Deviation, Comparison, Expressing, Produced, Software, Incubation, Control